Table 1.
Main characteristics of patients with GD included in this study.
| BT | AT | Range | |
|---|---|---|---|
| Number | 36 | 21 | |
| Gender (M/F) | 9/27 | 4/17 | |
| Age (years) | 36.33 ± 14.08 | 36.83 ± 14.08 | |
| T3 (nmol/L) | 3.36 ± 2.70 | 2.15 ± 0.78 | 1.02-2.96 |
| T4 (nmol/L) | 155.43 ± 91.10 | 113.99 ± 26.25 | 55.47-161.25 |
| FT3 (pmol/L) | 11.13 ± 8.70 | 4.24 ± 0.47 | 2.77-6.31 |
| FT4 (pmol/L) | 29.01 ± 25.56 | 15.01 ± 5.23 | 10.45-24.38 |
| TSH (mIU/L) | 0.032 ± 0.040 | 1.809 ± 1.534 | 0.380-4.340 |
| Tg-Ab (U/mL) | 207.49 ± 242.63 | 65.46 ± 48.52 | <60 |
| TPO-Ab (IU/mL) | 1225.67 ± 1275.55 | 711.59 ± 1237.49 | <100 |
Note: data are presented as mean ± standard deviation. M/F: male/female; BT: before treatment with new diagnosis; AT: after treatment; TSH: thyroid-stimulating hormone; T3: triiodothyronine; T4: thyroxine; FT3: free T3; FT4: free T4; Tg-Ab: thyroglobulin antibody; TPO-Ab: thyroperoxidase antibody.